Biovoca FDA Approval: A late qualifier for a pole position - Redeye

Finally, Biovica has secured US approval (510k) for DiviTum in the core market indication. The approval is to use DiviTum to aid in monitoring disease progression in previously diagnosed hormone receptor-positive, metastatic postmenopausal female breast cancer mBC. The company is now a Dx (broad sense) with an approved clinical marker on the US market.

Länk till analysen i sin helhet: https://www.redeye.se/research/849782/biovoca-fda-approval-a-late-qualifier-for-a-pole-position?utm_source=finwire&utm_medium=RSS